The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome
Open accessAbstract
BACKGROUND: Accumulating evidence supports the view that an imbalance of gut bacteria contributes to IBS, and that increasing the mass of beneficial species may reduce the numbers of pathogenic bacteria and help alleviate symptoms. METHODS: In this double-blind trial 400 adult patients with moderate-to-severe symptomatic diarrhea-predominant IBS (IBS-D) were randomized to treatment with the multi-strain probiotic Bio-Kult® (14 different bacterial strains) or placebo for 16 weeks. The change in severity and frequency of abdominal pain was the primary outcome measure. RESULTS: Probiotic treatment significantly improved the severity of abdominal pain in patients with IBS-D. A 69% reduction for probiotic versus 47% for placebo (p < 0.001) equates to a 145 point reduction on the IBS-severity scoring system (IBS-SSS). The proportion of patients who rated their symptoms as moderate-to-severe was reduced from 100% at baseline to 14% for the multi-strain probiotic at follow-up (month 5) versus 48% for placebo (p < 0.001). Also, the number of bowel motions per day from month 2 onwards was significantly reduced in the probiotic group compared with the placebo group (p < 0.05). In addition to relieving symptoms, the probiotic markedly improved all dimensions of quality of life in the 34-item IBS-Quality of Life (IBS-QoL) questionnaire. No serious adverse events were reported. CONCLUSIONS: The multi-strain probiotic was associated with significant improvement in symptoms in patients with IBS-D and was well-tolerated. These results suggest that probiotics confer a benefit in IBS-D patients which deserves further investigation. TRIAL REGISTRATION: [Clinicaltrials.gov NCT03251625 ; retrospectively registered on August 9, 2017].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155 · cited 1×
“The prevalence of IBS varies between geographic regions and populations, and is also dependent upon the diagnostic criteria used [4].”
The microbiome and innate immunity
Thaiss, C. A., Zmora, N., Levy, M., & Elinav, E. (2016) · Nature · doi:10.1038/nature18847 · Cited by 2,012 · cited 1×
“It is undeniable that the gut microbiota has both direct and indirect effects on the immune system and inflammation [44, 45].”
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846 · cited 1×
“It is undeniable that the gut microbiota has both direct and indirect effects on the immune system and inflammation [44, 45].”
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“The IBS-SSS is a 5-item instrument used to measure severity of abdominal pain, frequency of abdominal pain (number of days with abdominal pain over the last 10 days), severity of abdominal distension, dissatisfaction with bowel habits, and interference with quality of life, each on a 100-point scale [35].”
Towards positive diagnosis of the irritable bowel.
Manning, A. P., Thompson, W. G., Heaton, K. W., & Morris, A. F. (1978) · BMJ · doi:10.1136/bmj.2.6138.653 · Cited by 1,374
Irritable Bowel Syndrome: A Clinical Review
Chey, W. D., Kurlander, J., & Eswaran, S. (2015) · JAMA · doi:10.1001/jama.2015.0954 · Cited by 1,081
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome
Saulnier, D. M., Riehle, K., Mistretta, T., Diaz, M., Mandal, D., Raza, S., Weidler, E. M., Qin, X., Coarfa, C., Milosavljevic, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.072 · Cited by 672 · cited 1×
“A decreased abundance of Bifidobacterium and Lactobacillus species [22], and an increase in Gammaproteobacteria species (a family comprised of numerous pathogens) [23] is frequently reported in IBS studies.”
Irritable bowel syndrome in the general population.
Jones, R., & Lydeard, S. (1992) · BMJ · doi:10.1136/bmj.304.6819.87 · Cited by 636 · cited 1×
“Despite being highly symptomatic and negatively impacting the individual’s quality of life (QoL), it has been noted that only about one-third of patients present to their general practitioners [9].”
Sperber, A. D., Dumitrascu, D., Fukudo, S., Gerson, C., Ghoshal, U. C., Gwee, K. A., Hungin, A. P. S., Kang, J.-Y., Minhu, C., Schmulson, M., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311240 · Cited by 554 · cited 1×
“Background Irritable bowel syndrome (IBS) is a common highly prevalent functional gastrointestinal (GI) disorder that places an enormous burden on resource-challenged healthcare systems [1, 2].”
Research works printed but not linked: 1
- Drossman DA, Richter JE, Talley NJ. The functional gastrointestinal bowel disorders, pathophysiology and treatment: a multinational consensus. Boston: Little Brown; 1994.
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics
Guarner, F., Sanders, M. E., Szajewska, H., Cohen, H., Eliakim, R., Herrera-deGuise, C., Karakan, T., Merenstein, D., Piscoya, A., Ramakrishna, B., et al. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002002 · Cited by 209
Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review
Dale, H. F., Rasmussen, S. H., Asiller, Ö. Ö., & Lied, G. A. (2019) · Nutrients · doi:10.3390/nu11092048 · Cited by 166
AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
Preidis, G. A., Weizman, A. V., Kashyap, P., & Morgan, R. L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.060 · Cited by 149
Johnson, D., Thurairajasingam, S., Letchumanan, V., Chan, K., & Lee, L. (2021) · Nutrients · doi:10.3390/nu13051728 · Cited by 138
Metadata
- Authors
- Ishaque, S. M., Khosruzzaman, S. M., Ahmed, D. S., & Sah, M. P.
- Affiliations
- Bangladesh Medical University (BD)
- Corresponding author
- Ishaque, Shamsuddin M.
- Venue
- BMC Gastroenterology
- Published
- 2018-05-25
- Volume
- 18
- Issue
- 1
- Pages
- 71-71
- ISSN
- 1471-230X (ISSN-L)
- PMC
- PMC5970461
- OpenAlex
- W2807175397
- Cited by
- 109
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 19 · 2023: 22 · 2022: 7 · 2021: 16 · 2020: 16 · 2019: 7 · 2018: 1
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Gastroenterology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, multi-strain probiotics, diarrhea-predominant irritable bowel syndrome, abdominal pain, stool frequency, quality of life, gut microbiota, IBS symptom severity
- MeSH terms
- Gastrointestinal Microbiome, Adolescent, Adult, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Quality of Life, Severity of Illness Index, Abdominal Pain, Probiotics, Irritable Bowel Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. https://app.cochat.ai/papers/10.1186/s12876-018-0788-9
- The paper
- Ishaque, S. M., Khosruzzaman, S. M., Ahmed, D. S., & Sah, M. P. (2018). A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterology. https://doi.org/10.1186/s12876-018-0788-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.